4.6 Article

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2010.03.029

Keywords

Cisplatin resistance; Ovarian cancer cells; Akt; mTOR; Apoptosis

Funding

  1. NIH [R01 CA100073]
  2. Gail Purtan Ovarian Cancer Research Fund

Ask authors/readers for more resources

The mechanism of cisplatin resistance in cancer cells is not fully understood Here, we show that the Akt/ mTOR survival pathway plays an important role in cisplatin resistance in human ovarian cancer cells Specifically, we found that cisplatin treatment activates the Akt/mTOR survival pathway and that inhibition of this pathway by the PI3 K inhibitor LY294002 or knockdown of Akt sensitizes ovarian cancer cells to cisplatin Furthermore, we generated cisplatin-resistant cells and found that resistant cells express a higher level of activated Akt as compared to their cisplatin sensitive counterparts Importantly, inhibition of Akt or mTOR sensitized resistant cells to cisplatin-induced apoptosis Taken together, our data indicate that activation of the Akt/mTOR pathway prevents cisplatin-induced apoptosis, leading to cisplatin resistance Therefore, our study suggests that cisplatin resistance can be overcome by targeting the Akt/mTOR survival pathway in human ovarian cancer cells (C) 2010 Elsevier Inc All rights reserved

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available